Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study

References

• Ibrahim RM, Steenstrup Jensen S, Juel J. Clear cell sarcoma-a review. J Orthop. 2018;15(4):963–966. doi:10.1016/j.jor.2018.08.03930210202
   PubMed Web of Science ®Google Scholar
• Yang Z, Zheng R, Zhang S, et al. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019;16(3):565–574. doi:10.20892/j.issn.2095-3941.2019.004131565485
   PubMed Web of Science ®Google Scholar
• Clark MA, Johnson MB, Thway K, et al. Clear cell sarcoma (melanoma of soft parts): the Royal Marsden Hospital experience. Eur J Surg Oncol. 2008;34(7):800–804. doi:10.1016/j.ejso.2007.10.00618042498
   PubMed Web of Science ®Google Scholar
• Malchau SS, Hayden J, Hornicek F, et al. Clear cell sarcoma of soft tissues. J Surg Oncol. 2007;95(6):519–522. doi:10.1002/jso.2073017192915
   PubMed Web of Science ®Google Scholar
• Yang L, Chen Y, Cui T, et al. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol. 2012;43(9):1463–1470. doi:10.1016/j.humpath.2011.10.02222406360
   PubMed Web of Science ®Google Scholar
• Hocar O, Le Cesne A, Berissi S, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012;2012:984096. doi:10.1155/2012/98409622693489
   PubMedGoogle Scholar
• Ipach I, Mittag F, Kopp HG, et al. Clear-cell sarcoma of the soft tissue–a rare diagnosis with a fatal outcome. Eur J Cancer Care (Engl). 2012;21(3):412–420. doi:10.1111/j.1365-2354.2011.01318.x22150806
   PubMed Web of Science ®Google Scholar
• Blazer DG, Lazar AJ, Xing Y, et al. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer. 2009;115:2971–2979. doi:10.1002/cncr.2432219402173
   PubMed Web of Science ®Google Scholar
• Cornillie J, van Cann T, Wozniak A, et al. Biology and management of clear cell sarcoma: state of the art and future perspectives. Expert Rev Anticancer Ther. 2016;16(8):839–845. doi:10.1080/14737140.2016.119712227253849
   PubMed Web of Science ®Google Scholar
• Jones RL, Constantinidou A, Thway K, et al. Chemotherapy in clear cell sarcoma. Med Oncol. 2011;28(3):859–863. doi:10.1007/s12032-010-9502-720390470
   PubMed Web of Science ®Google Scholar
• Li AB, Jiang BJ, Wang HH, et al. Prognostic factors for survival in patients with clear cell sarcoma: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Med Sci Monit. 2019;25:6950–6956. doi:10.12659/MSM.91670531522190
   PubMed Web of Science ®Google Scholar
• Chen S, Luo P, Yang L, et al. Prognostic analysis of surgically treated clear cell sarcoma: an analysis of a rare tumor from a single center. Int J Clin Oncol. 2019;24(12):1605–1611. doi:10.1007/s10147-019-01487-x31243628
   PubMed Web of Science ®Google Scholar
• Gonzaga MI, Grant L, Curtin C, et al. The epidemiology and survivorship of clear cell sarcoma: a National Cancer Database (NCDB) review. J Cancer Res Clin Oncol. 2018;144(9):1711–1716. doi:10.1007/s00432-018-2693-629961184
   PubMed Web of Science ®Google Scholar
• Schoffski P, Wozniak A, Stacchiotti S, et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Ann Oncol. 2017;28(12):3000–3008. doi:10.1093/annonc/mdx52728950372
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-376629895706
   PubMed Web of Science ®Google Scholar
• Siozopoulou V, Domen A, Zwaenepoel K, et al. Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel? Cancers (Basel). 2021;13(2):360. doi:10.3390/cancers1302036033478080
   PubMed Web of Science ®Google Scholar
• Yang QK, Chen T, Wang SQ, et al. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis. 2020;23(3):279–298. doi:10.1007/s10456-020-09716-y32333216
   PubMed Web of Science ®Google Scholar
• Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020;8(1):e000798. doi:10.1136/jitc-2020-00079832376724
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhang Y, Yu YH. Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report. Ann Palliat Med. 2021;10:785–792. doi:10.21037/apm-20-227533545800
   PubMed Web of Science ®Google Scholar
• Tian Z, Wang X, Liu Z, et al. Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions. Cancer Manag Res. 2019;11:5293–5300. doi:10.2147/CMAR.S20715031239779
   PubMed Web of Science ®Google Scholar
• Tian Z, Liu H, Zhang F, et al. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma. Invest New Drugs. 2020;38(5):1559–1569. doi:10.1007/s10637-020-00912-732100146
   PubMed Web of Science ®Google Scholar
• Tian Z, Yang Y, Yang Y, et al. High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer. 2020;20(1):1139. doi:10.1186/s12885-020-07663-x33228579
   PubMed Web of Science ®Google Scholar
• Tian Z, Yang Y, Yang J, et al. Safety and efficacy of PD-1 inhibitors plus chemotherapy in advanced soft tissue sarcomas: a retrospective study. Cancer Manag Res. 2020;12:1339–1346. doi:10.2147/CMAR.S23730032158266
   PubMed Web of Science ®Google Scholar
• Urakawa H, Kawai A, Goto T, et al. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: a Japanese Musculoskeletal Oncology Group study. Cancer Sci. 2020;111:3303–3312. doi:10.1111/cas.1454232579783
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Grosso F, Negri T, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol. 2010;21(5):1130–1131. doi:10.1093/annonc/mdp61120093352
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380. doi:10.1111/j.1349-7006.2011.01939.x21443688
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S. (Pre‐)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539–547. doi:10.1634/theoncologist.2009-027420511320
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–1219. doi:10.1111/cas.1353629446853
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-sm all cell lung cancer according to MET alterations. J Thorac Oncol. 2011;6(10):1624–1631. doi:10.1097/JTO.0b013e31822591e921716144
   PubMed Web of Science ®Google Scholar
• Roy S, Narang BK, Rastogi SK, et al. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib. Anticancer Agents Med Chem. 2015;15(1):37–47. doi:10.2174/187152061466614090215384025181996
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493–1501. doi:10.1016/S1470-2045(17)30624-128988646
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-la bel, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416–426. doi:10.1016/S1470-2045(18)30006-829370992
   PubMed Web of Science ®Google Scholar
• Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(6):837–848. doi:10.1016/S1470-2045(19)30153-631078463
   PubMed Web of Science ®Google Scholar
• Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020;8(2):e001561. doi:10.1136/jitc-2020-00156133203665
   PubMed Web of Science ®Google Scholar
• Lan C, Shen J, Wang Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2020;38(34):4095–4106. doi:10.1200/JCO.20.0192033052760
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhao J, Wang Q, et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial. J Thorac Oncol. 2020;16(2):299–309. doi:10.1016/j.jtho.2020.10.00233166719
   PubMed Web of Science ®Google Scholar
• Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2020;27(4):1003–1011. doi:10.1158/1078-0432.CCR-20-257133087333
   PubMed Web of Science ®Google Scholar